TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in health behavior in relation to physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ibrutinib plasma concentrations after administration on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ibrutinib plasma concentrations after administration on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite PCI-45227 plasma concentrations after administration on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite PCI-45227 plasma concentrations after administration on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) at 36 Months
Endpoint domain: Mortality/survival
Primary endpoint: Correlation of HepaFat-Scan with pathology based assessment of steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of HepaFat-Scan measurement with magnetic resonance spectroscopy (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of HepaFat-Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of events of angiographic binary restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Slope of oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of scores on the Subjective Units of Distress (SUD) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Transpulmonary driving pressure (ΔPtp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic ability measured by AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Criminal recidivism based on self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Criminal recidivism based on official records
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Substance use abstinence based on self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Second progress-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Patient knowledge regarding CTO of PCI or medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone formation around dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of sinus venous thrombosis severity scale (SVTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth during first three weeks of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factual knowledge about newborn screening
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Factual knowledge about newborn blood spots retention and use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TDI-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge related to blood pressure and lipid management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment-emergent Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prognosis of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated survival rate without molecular relapse
Endpoint domain: Mortality/survival
Primary endpoint: Corrected carotid artery flow time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EASI (Eczema Area and Severity Index) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of subjective breast sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Level of distress related to breast sensations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients on European LDL-C target at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Language Quotient of the Western Aphasia Battery-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve up to the last quantifiable plasma concentration (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum BIWH 3 plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median serum ketone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: knowledge of Warfarin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of contrast related nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of contrast allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of PSMA and Cu-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of solicited local and general adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any unsolicited AE
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subject satisfaction on penile appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Probability of having a child with bilateral retinoblastoma
Endpoint domain: Mortality/survival
Primary endpoint: Probability of mothers of unilateral RB cases having specific DNA-repair gene variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Significant effect of specific DNA repair and CME genotypes on the risk of unilateral RB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urine creatinine comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine Albumin comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in obsessive and compulsive symptoms and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in level of overvalued ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in menstrual pain from baseline to 12-months post baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of morphine administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intracranial Pressure (ICP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced at Least One Serious Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Relevant Changes in Vital Sign Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Relevant Changes in Clinical Laboratory Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Relevant Changes in Electrocardiogram Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Virological suppression (HIV-1 RNA below 50 copies/mL plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Airway Submucosal Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of gambling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of structural damage (radiographic progression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motile Total Sperm Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Specificity of Transimpedance Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of H2O2 in the aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Good Drug Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-reported Quit Attempts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seven-day Point Prevalence of Quit Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression Along the Stage of Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Objective response rate (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No hidden insulinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Days of Heroin Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levonorgestrel serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale 0-1 (favourable outcome)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complication after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Total Hip Bone Mineral Density Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of relapse or progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hamilton Rating Scale for Depression-Seasonal Affective Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent Understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Virological resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rate at End of Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Parenteral Opioid Use in IV Morphine Equivalents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical improvement of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of wound contraction and re-epithelialisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete healing time for investigated burn area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Parenting Behavior Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Self-Efficacy and Beliefs Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Behavior Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gut Microbiota Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the curve for fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Couples Satisfaction Index (CSI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inventory of Psychosocial Functioning (IPF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GAI scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak myocardial velocity (Sm) during the ejection phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Pain Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort Measurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: elevated liver function tests (AST, ALT, total bilirubin, direct bilirubin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Night-time breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: global skeletal muscle gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: true identification of an orbital tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in saliva proteomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical length after vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-month Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Abortion Rate
Endpoint domain: Mortality/survival
Primary endpoint: Implantation Rate
Endpoint domain: Mortality/survival
Primary endpoint: Maternal sensitivity and responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of postural deformities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to advanced diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: changes of cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold Change in VZV-Specific IgG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuro-muscular block resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Daily Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal sprinting speed over 10 meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal sprinting speed over 30 meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative urinary retention
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of drug crossing from plasma to brain (ki)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combination maximum tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Total Hammersmith Functional Motor scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with free and/or reduced gynecological infection symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 30-day all cause mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: All cause clinical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycodelin-A endometrial expression pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early wound healing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in probing pocket depth and clinical attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical parameters of gingival index and plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful placement of Tube in the Trachea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interferon effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in post-operative care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Accuracy of the Decision Aid Prototype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensibility of the Decision Aid Prototype
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Usability of the Decision Aid Prototype
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decreased pain after mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knowledge of child development and parenting
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Reading Practices
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: AUC0-24h of YH4808
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24h of M3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of M3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal CK-MB level post-PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in MADRS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Confirmation of suspected infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of medication days per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of antibodies to AMG 557
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma concentration (Cmax) of Entecavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve, last (AUClast) of entecavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: main adverse cardiovascular and cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Macular-center thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HBs antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by incidence, severity, and causality of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability as assessed by incidence and severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: plasma measurements of DM199
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DM199 urine concentrations of KLK1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific elastance of the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fasting and non-fasting plasma lipids, apolipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Macula Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Timing of plasma melatonin increase under dim-light conditions (dim-light melatonin onset)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes